CVA Family Office LLC Has $334,000 Stake in Pfizer Inc. (NYSE:PFE)

CVA Family Office LLC raised its position in Pfizer Inc. (NYSE:PFE) by 14.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 9,109 shares of the biopharmaceutical company’s stock after purchasing an additional 1,177 shares during the period. CVA Family Office LLC’s holdings in Pfizer were worth $334,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Corbett Road Capital Management LLC bought a new position in shares of Pfizer in the 2nd quarter valued at about $25,000. Reitz Capital Advisors LLC bought a new position in shares of Pfizer in the 2nd quarter valued at about $29,000. Rocky Mountain Advisers LLC grew its holdings in shares of Pfizer by 847.5% in the 2nd quarter. Rocky Mountain Advisers LLC now owns 1,118 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,000 shares in the last quarter. JJJ Advisors Inc. bought a new position in shares of Pfizer in the 2nd quarter valued at about $44,000. Finally, NuWave Investment Management LLC grew its holdings in shares of Pfizer by 439.7% in the 3rd quarter. NuWave Investment Management LLC now owns 1,468 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 1,196 shares in the last quarter. 69.08% of the stock is currently owned by hedge funds and other institutional investors.

In other Pfizer news, Director Ronald E. Blaylock purchased 13,000 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was bought at an average cost of $38.55 per share, for a total transaction of $501,150.00. Following the completion of the transaction, the director now owns 4,000 shares in the company, valued at $154,200. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Pfizer Inc purchased 1,200,000 shares of the company’s stock in a transaction dated Tuesday, October 27th. The stock was acquired at an average price of $10.00 per share, with a total value of $12,000,000.00. Following the completion of the transaction, the insider now owns 27,349,211 shares of the company’s stock, valued at approximately $273,492,110. The disclosure for this purchase can be found here. 0.08% of the stock is currently owned by insiders.

Several equities analysts have recently weighed in on the company. Morgan Stanley raised their price objective on Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating and set a $37.00 price objective for the company in a report on Thursday. Atlantic Securities cut Pfizer from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $44.00 to $39.00 in a report on Monday, October 12th. ValuEngine cut Pfizer from a “hold” rating to a “sell” rating in a report on Thursday, July 30th. Finally, Berenberg Bank began coverage on Pfizer in a report on Tuesday, September 29th. They set a “hold” rating and a $38.00 price target for the company. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $39.66.

PFE stock traded down $0.33 during mid-day trading on Friday, hitting $34.95. 808,125 shares of the company were exchanged, compared to its average volume of 28,428,533. The business has a 50 day simple moving average of $36.74 and a 200-day simple moving average of $36.59. The company has a current ratio of 1.42, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $196.05 billion, a PE ratio of 13.88, a price-to-earnings-growth ratio of 3.10 and a beta of 0.66. Pfizer Inc. has a 1-year low of $27.88 and a 1-year high of $40.97.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 27th. The biopharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.01. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The firm had revenue of $12.13 billion during the quarter, compared to the consensus estimate of $12.30 billion. During the same period last year, the business posted $0.75 earnings per share. The business’s revenue for the quarter was down 4.3% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post 2.84 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, November 6th will be given a $0.38 dividend. The ex-dividend date is Thursday, November 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.35%. Pfizer’s payout ratio is 51.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: Cost of Goods Sold (COGS)

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.